Quadrant Capital Group’s Praxis Precision Medicines PRAX Stock Holding History

Quadrant Capital Group’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$323	–	2226
2026 Q1	$323	Buy	+1	New	+$309	﹤0.01%	2648
2022 Q3	–	Sell	-27	Closed	-$1K	–	2768
2022 Q2	$1K	Buy	+27	New	+$2.88K	﹤0.01%	2429
2022 Q1	–	Sell	-3	Closed	-$1K	–	2652
2021 Q4	$1K	Sell	3 -5	-63%	-$1.47K	﹤0.01%	2378
2021 Q3	$2K	Buy	+8	New	+$2.17K	﹤0.01%	2177

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Quadrant Capital Group's PRAX Position: Q2 2026 in Review

Quadrant Capital Group sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 1 share — an estimated $323 sold.

Quadrant Capital Group first reported a position in PRAX in Q3 2021 and held it in 4 quarters. The position peaked at $2K in Q3 2021. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Quadrant Capital Group reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
Quadrant Capital Group sold 1 Praxis Precision Medicines share in Q2 2026, an estimated $323.
Quadrant Capital Group first reported a position in Praxis Precision Medicines in Q3 2021 and held it in 4 quarters.
Quadrant Capital Group's Praxis Precision Medicines position peaked at $2K in Q3 2021.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.